Tyra Biosciences to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotech company specializing in FGFR-targeted precision medicines, has announced its participation in three upcoming investor conferences. The company will attend the Bank of America Global Healthcare Conference (May 13-15) in Las Vegas, featuring a fireside chat on May 13 at 5:15 PM PT. Additionally, TYRA will participate in the Jefferies Global Healthcare Conference (June 3-5) and UBS Biotech 1x1 Symposium (June 24) in New York, both featuring one-on-one investor meetings. A webcast of the fireside chat will be accessible through TYRA's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TYRA declined 2.73%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Bank of America Global Healthcare Conference, May 13-15, 2025
- Format: Fireside chat and one-on-one investor meetings
- Presentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PT
- Location:
Las Vegas, NV
- Jefferies Global Healthcare Conference, June 3-5, 2025
- Format: One-on-one investor meetings
- Location: New
York, NY
- UBS Biotech 1x1 Symposium, June 24, 2025
- Format: One-on-one investor meetings
- Location: New
York, NY
A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-participate-at-upcoming-investor-conferences-302452593.html
SOURCE Tyra Biosciences
FAQ
What investor conferences will TYRA stock attend in May and June 2025?
When is Tyra Biosciences' (TYRA) fireside chat at the Bank of America conference?
Where can investors watch Tyra Biosciences' (TYRA) conference presentation?
What is Tyra Biosciences' (TYRA) main business focus?
